MedVenture Partners
VC Fund
Tokyo, Japan
MedVenture Partners is a VC fund in Tokyo focused on Medical Device and Health Care. MedVenture Partners invests in seed to early stage projects and start-ups in the life science field focusing mainly on medical devices.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 56%
- Fund size:
- $9.2M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries MedVenture Partners invests in
Stages MedVenture Partners invests in
Countries MedVenture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $931k–$11M
- Series B
- $2.4M–$10M
- Venture - Series Unknown
- $1.3M–$4.4M
Investment Focus
Industry
- Medical Device 10 (56%)
- Health Care 6 (33%)
- Manufacturing 4 (22%)
- Medical 3 (17%)
- Biotechnology 2 (11%)
Stage
- Series B 5 (28%)
- Series A 4 (22%)
- Venture - Series Unknown 4 (22%)
- Seed 3 (17%)
- Series C 1 (6%)
Country
- Japan 9 (50%)
- United States 4 (22%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Justin Fukuyama
Partner
|
Partner | Total investments: 1 | Find email | |
|
Hajime Oshita
President and CEO
|
President and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Avisi Technologies
|
Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $10.8M / Series A / Feb 25, 2026 | |
A-Wave
|
A-Wave is a manufacturing company that develops and markets medical devices, pharmaceuticals, computer software, and hardware. | $3.5M / Series B / Feb 17, 2026 | |
Quali
|
Quali is dedicated to developing innovative products and solutions that support microsurgery, with the goal of addressing critical challenges in the medical field and improving patient outcomes and overall quality of life. | $11.5M / Series A / Feb 06, 2026 | |
|
A-Wave
|
A-Wave is a manufacturing company that develops and markets medical devices, pharmaceuticals, computer software, and hardware. | $1.3M / Venture - Series Unknown / Oct 15, 2024 | |
MaRI
|
MaRI develops SAS technologies to solve daily sleep-blocking factors in a human-friendly way. They provide SAS devices to resolve hypopnea and apnea with low-frequency irradiation technology without burdening patients. Their non-contact SAS device also treats illnesses such as heart failure, arrhythmias, stroke, and diabetes. | $2.4M / Series B / Dec 22, 2023 | |
|
Avisi Technologies
|
Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $6.3M / Seed / Oct 01, 2023 | |
SentiAR
|
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $8.5M / Series B / Apr 11, 2023 | |
|
MaRI
|
MaRI develops SAS technologies to solve daily sleep-blocking factors in a human-friendly way. They provide SAS devices to resolve hypopnea and apnea with low-frequency irradiation technology without burdening patients. Their non-contact SAS device also treats illnesses such as heart failure, arrhythmias, stroke, and diabetes. | $2.6M / Series A / Jan 20, 2022 | |
mediVR
|
mediVR is a Medical equipment which applies the video technology of Virtual Reality, etc. In Co., Ltd. mediVR, planning of the health care system, has been developing and sales. | $4.6M / Series B / Jul 08, 2021 | |
CorVista Health
|
CorVista Health is an AI-driven medical company developing a cardiac diagnostic platform. Its platform is a non-invasive point-of-care solution allowing physicians to evaluate heart function without radiation, contrast agents, injections, fasting, or exercise. | $65M / Series C / Mar 04, 2021 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does MedVenture Partners invest in?
MedVenture Partners invests primarily in Medical Device, Health Care and Manufacturing startups, most often at Series B and Series A stage. Most of the 18 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is MedVenture Partners's check size?
MedVenture Partners typically joins rounds of $931k–$11M at Series A, $2.4M–$10M at Series B and $1.3M–$4.4M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds MedVenture Partners participates in.
How do I contact MedVenture Partners?
Public channels for MedVenture Partners include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MedVenture Partners?
The team at MedVenture Partners includes Justin Fukuyama (Partner) and Hajime Oshita (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
